Falls prechemotherapy and toxicity-related hospitalization during adjuvant chemotherapy for breast cancer in older women: Results from the prospective multicenter HOPE trial

被引:4
作者
Ji, Jingran [1 ]
Bae, Marie [1 ]
Sun, Can-Lan [1 ]
Wildes, Tanya M. [2 ]
Freedman, Rachel A. [3 ]
Magnuson, Allison [4 ]
O'Connor, Tracey [5 ]
Moy, Beverly [6 ]
Klepin, Heidi D. [7 ]
Chapman, Andrew E. [8 ]
Tew, William P. [9 ]
Dotan, Efrat [10 ]
Fenton, Mary Anne [11 ]
Kim, Heeyoung [1 ]
Katheria, Vani [1 ]
Gross, Cary P. [12 ]
Cohen, Harvey J. [13 ]
Muss, Hyman B. [14 ]
Sedrak, Mina S. [1 ,15 ,16 ]
机构
[1] City Hope Natl Med Ctr, Dept Med Oncol & Therapeut Res, Duarte, CA USA
[2] Univ Nebraska Med Ctr, Nebraska Med, Div Hematol Oncol, Omaha, NE USA
[3] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA
[4] Univ Rochester, Med Ctr, Dept Med, Rochester, NY USA
[5] H Lee Moffitt Canc Ctr & Res Inst, Dept Breast Oncol, Tampa, FL USA
[6] Massachusetts Gen Hosp, Dept Med, Boston, MA USA
[7] Wake Forest Sch Med, Dept Pathol Comparat Med, Winston Salem, NC USA
[8] Jefferson Hlth, Sidney Kimmel Canc Ctr, Dept Med Oncol, Philadelphia, PA USA
[9] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY USA
[10] Fox Chase Canc Ctr, Dept Hematol & Oncol, Philadelphia, PA USA
[11] Brown Univ, Dept Med, Providence, RI USA
[12] Yale Sch Med, Dept Med, New Haven, CT USA
[13] Duke Univ, Sch Med, Dept Med, Durham, NC USA
[14] Univ N Carolina, Dept Med, Chapel Hill, NC USA
[15] UCLA David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA
[16] UCLA David Geffen Sch Med, 650 Charles Young Dr South,Room A2-125 CHS, Los Angeles, CA 90095 USA
关键词
adjuvant chemotherapy; breast cancer; falls; geriatric assessment; hospitalization; older adults; toxicity; RISK-FACTORS; PHYSICAL-ACTIVITY; ADULTS; DISABILITY; MORTALITY; INJURIES; POLYPHARMACY; NEUTROPENIA; VALIDATION; MANAGEMENT;
D O I
10.1002/cncr.35105
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Older women with breast cancer frequently experience toxicity-related hospitalizations during adjuvant chemotherapy. Although the geriatric assessment can identify those at risk, its use in clinic remains limited. One simple, low-cost marker of vulnerability in older persons is fall history. Here, the authors examined whether falls prechemotherapy can identify older women at risk for toxicity-related hospitalization during adjuvant chemotherapy for breast cancer.Methods: In a prospective study of women >= 65 years old with stage I-III breast cancer treated with adjuvant chemotherapy, the authors assessed baseline falls in the past 6 months as a categorical variable: no fall, one fall, and more than one fall. The primary end point was incident hospitalization during chemotherapy attributable to toxicity. Multivariable logistic regression was used to examine the association between falls and toxicity-related hospitalization, adjusting for sociodemographic, disease, and geriatric covariates.Results: Of the 497 participants, 60 (12.1%) reported falling before chemotherapy, and 114 (22.9%) had one or more toxicity-related hospitalizations. After adjusting for sociodemographic, disease, and geriatric characteristics, women who fell more than once within 6 months before chemotherapy had greater odds of being hospitalized from toxicity during chemotherapy compared to women who did not fall (50.0% vs. 20.8% experienced toxicity-related hospitalization, odds ratio, 4.38; 95% confidence interval, 1.66-11.54, p = .003).Conclusions: In this cohort of older women with early breast cancer, women who experienced more than one fall before chemotherapy had an over 4-fold increased risk of toxicity-related hospitalization during chemotherapy, independent of sociodemographic, disease, and geriatric factors.
引用
收藏
页码:936 / 946
页数:11
相关论文
共 50 条
  • [41] Efficacy of adjuvant chemotherapy schedules for breast cancer according to body mass index: results from the phase III GIM2 trial
    Poggio, F.
    Blondeaux, E.
    Tagliamento, M.
    Perachino, M.
    Nardin, S.
    Conte, B.
    Giuliano, M.
    Arpino, G.
    De Laurentiis, M.
    Gravina, A.
    Bisagni, G.
    Rimanti, A.
    Turletti, A.
    Nistico, C.
    Magnolfi, E.
    Gasparro, S.
    Fabi, A.
    Garrone, O.
    Alicicco, M. G.
    Urracci, Y.
    Poletti, P.
    Correale, P.
    Molinelli, C.
    Fozza, A.
    Puglisi, F.
    Colantuoni, G.
    Fregatti, P.
    Boni, L.
    Lambertini, M.
    Del Mastro, L.
    ESMO OPEN, 2024, 9 (08)
  • [42] Efficacy and Safety of Tailored and Dose-Dense Adjuvant Chemotherapy and Trastuzumab for Resected HER2-Positive Breast Cancer: Results From the Phase 3 PANTHER Trial
    Papakonstantinou, Antroula
    Matikas, Alexios
    Bengtsson, Nils Olof
    Malmstrom, Per
    Hedayati, Elham
    Steger, Guenther
    Untch, Michael
    Hubbert, Laila
    Johansson, Hemming
    Hellstrom, Mats
    Gnant, Michael
    Loibl, Sibylle
    Greil, Richard
    Moebus, Volker
    Foukakis, Theodoros
    Bergh, Jonas
    CANCER, 2020, 126 (06) : 1175 - 1182
  • [43] Decision of adjuvant chemotherapy in intermediate risk luminal breast cancer patients: A prospective multicenter trial assessing the clinical and psychological impact of EndoPredict® (EpClin) use (UCBG 2-14)
    Penault-Llorca, Frederique
    Kwiatkowski, Fabrice
    Arnaud, Antoine
    Levy, Christelle
    Leheurteur, Marianne
    Uwer, Lionel
    Derbel, Olfa
    Le Rol, Annick
    Jacquin, Jean-Philippe
    Jouannaud, Christelle
    Quenel-Tueux, Nathalie
    Girre, Veronique
    Foa, Cyril
    Guardiola, Emmanuel
    Lortholary, Alain
    Catala, Stephanie
    Guiu, Severine
    Valent, Alexander
    Boinon, Diane
    Lemonnier, Jerome
    Delaloge, Suzette
    BREAST, 2020, 49 : 132 - 140
  • [44] Prognostic Impact of Weight Change During Adjuvant Chemotherapy in Patients With High-Risk Early Breast Cancer: Results From the ADEBAR Study
    Mutschler, Nikola S.
    Scholz, Christoph
    Friedl, Thomas W. P.
    Zwingers, Thomas
    Fasching, Peter A.
    Beckmann, Matthias W.
    Fehm, Tanja
    Mohrmann, Svjetlana
    Salmen, Jessica
    Ziegler, Carola
    Jaeger, Bernadette
    Widschwendter, Peter
    de Gregorio, Nikolaus
    Schochter, Fabienne
    Mahner, Sven
    Harbeck, Nadia
    Weissenbacher, Tobias
    Jueckstock, Julia
    Janni, Wolfgang
    Rack, Brigitte
    CLINICAL BREAST CANCER, 2018, 18 (02) : 175 - 183
  • [45] Adjuvant breast radiotherapy, endocrine therapy, or both after breast conserving surgery in older women with low-risk breast cancer: Results from a population-based study
    Joseph, Kurian
    Zebak, Sarah
    Alba, Veronica
    Mah, Kayla
    Au, Cara
    Vos, Larissa
    Ghosh, Sunita
    Abraham, Aswin
    Chafe, Susan
    Wiebe, Ericka
    Liu, Hong-Wei
    Chambers, Carole
    Gabos, Zsolt
    Tankel, Keith
    Lupichuk, Sasha
    King, Karen
    RADIOTHERAPY AND ONCOLOGY, 2021, 154 : 93 - 100
  • [46] The impact of actual body weight-based chemotherapy dosing and body size on adverse events and outcome in older patients with breast cancer: Results from Cancer and Leukemia Group B (CALGB) trial 49907 (Alliance A151436)
    Morrison, Vicki A.
    McCall, Linda
    Muss, Hyman B.
    Jatoi, Aminah
    Cohen, Harvey J.
    Cirrincione, Constance T.
    Ligibel, Jennifer A.
    Lafky, Jacqueline M.
    Hurria, Arti
    JOURNAL OF GERIATRIC ONCOLOGY, 2018, 9 (03) : 228 - 234
  • [47] Exploring patient- and physician-related factors preventing breast cancer patients from guideline-adherent adjuvant chemotherapy—results from the prospective multi-center study BRENDA II
    Lukas Schwentner
    Reyn Van Ewijk
    Thorsten Kühn
    Felix Flock
    Riccardo Felberbaum
    Maria Blettner
    Rolf Kreienberg
    Wolfgang Janni
    Achim Wöckel
    Susanne Singer
    Supportive Care in Cancer, 2016, 24 : 2759 - 2766
  • [48] Effects of an Exercise and Nutritional Intervention on Circulating Biomarkers and Metabolomic Profiling During Adjuvant Treatment for Localized Breast Cancer: Results From the PASAPAS Feasibility Randomized Controlled Trial
    Febvey-Combes, Olivia
    Jobard, Elodie
    Rossary, Adrien
    Pialoux, Vincent
    Foucaut, Aude-Marie
    Morelle, Magali
    Delrieu, Lidia
    Martin, Agnes
    Caldefie-Chezet, Florence
    Touillaud, Marina
    Berthouze, Sophie E.
    Boumaza, Houda
    Elena-Herrmann, Benedicte
    Bachmann, Patrick
    Tredan, Olivier
    Vasson, Marie-Paule
    Fervers, Beatrice
    INTEGRATIVE CANCER THERAPIES, 2021, 20
  • [49] RANDOMIZED ADJUVANT TRIAL TO EVALUATE THE ADDITION OF TAMOXIFEN AND PSK TO CHEMOTHERAPY IN PATIENTS WITH PRIMARY BREAST-CANCER - 5-YEAR RESULTS FROM THE NISHI-NIPPON GROUP OF THE ADJUVANT CHEMOENDOCRINE THERAPY FOR BREAST-CANCER ORGANIZATION
    TOI, M
    HATTORI, T
    AKAGI, M
    INOKUCHI, K
    ORITA, K
    SUGIMACHI, K
    DOHI, K
    NOMURA, Y
    MONDEN, Y
    HAMADA, Y
    MORIMOTO, T
    OGAWA, N
    CANCER, 1992, 70 (10) : 2475 - 2483
  • [50] Optimal duration of adjuvant chemotherapy for high-risk node-negative (N-) breast cancer patients: 6-year results of the prospective randomised multicentre phase III UNICANCER-PACS 05 trial (UCBG-0106)
    Kerbrat, Pierre
    Desmoulins, Isabelle
    Roca, Lise
    Levy, Christelle
    Lortholary, Alain
    Marre, Alain
    Delva, Remy
    Rios, Maria
    Viens, Patrice
    Brain, Etienne
    Serin, Daniel
    Edel, Magali
    Debled, Marc
    Campone, Mario
    Mourret-Reynier, Marie-Ange
    Bachelot, Thomas
    Foucher-Goudier, Marie-Josephe
    Asselain, Bernard
    Lemonnier, Jerome
    Martin, Anne-Laure
    Roche, Henri
    EUROPEAN JOURNAL OF CANCER, 2017, 79 : 166 - 175